More than 5 years of European Paediatric Regulation: statistics and industrial experience

Area of Science:

• Regulatory Science
• Paediatric Pharmacology
• Drug Development

Background:

• European Union legislation aims to improve paediatric clinical research quality.
• Increased availability of child-appropriate medicines and better drug information are key goals.
• The Paediatric Investigation Plan (PIP) is a central component of this regulation.

Purpose of the Study:

• To summarize the achievements of European paediatric legislation since its 2007 introduction.
• To present case studies illustrating challenges with the Paediatric Investigation Plan (PIP) process.
• To highlight the impact of PIPs on paediatric drug development.

Main Methods:

• Review of regulatory achievements post-2007.
• Analysis of Paediatric Investigation Plan (PIP) case studies.
• Qualitative assessment of challenges in the PIP process.

Main Results:

• The regulation has mandated PIP submission and approval for new drug registrations in the EU.
• Case studies reveal practical challenges in implementing the PIP framework.
• The process aims to ensure new medicines are suitable for paediatric populations.

Conclusions:

• European paediatric legislation, centered on PIPs, is crucial for advancing child medicine research.
• Ongoing challenges exist in the practical application of the PIP process.
• The regulation is driving improvements in paediatric drug development and information.